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Targeting the tumor microenvironment is critical toward improving the effectiveness of cancer therapeutics. Cancer-
associated fibroblasts (CAFs) are one of the most abundant cell types of the tumor microenvironment, playing an
important role in tumor progression. Multiple origins for CAFs have been proposed including resident fibroblasts,
adipocytes, and bonemarrow.Our laboratory previously identified a novel hematopoietic stemcell (HSC) origin for CAFs;
however, the functional roles ofHSC-derivedCAFs (HSC-CAFs) in tumor progression have not yet been examined. To test
the hypothesis that HSC-CAFs promote tumor progression through contribution to extracellular matrix (ECM) and
paracrine production of pro-angiogenic factors,wedeveloped amethod to isolateHSC-CAFs.HSC-CAFswere profiled on
the basis of their expression of hematopoietic and fibroblastic markers in two murine tumor models. Profiling revealed
production of factors associated with ECM deposition and remodeling. Functional in vivo studies showed that co-
injection ofHSC-CAFswith tumor cells resulted in increased tumor growth rate and significantly larger tumors than tumor
cells alone. Immunohistochemical studies revealed increased blood vessel density with co-injection, demonstrating a
role for HSC-CAFs in tumor vascularization. Mechanistic in vitro studies indicated that HSC-CAFs play a role in producing
vascular endothelial growth factor A and transforming growth factor–β1 in endothelial tube formation and patterning.
In vitro and in vivo findings suggest that HSC-CAFs are a critical component of the tumormicroenvironment and suggest
that targeting the novel HSC-CAF may be a promising therapeutic strategy.
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Studies suggest that cancer-associated fibroblasts (CAFs) are
associated with increased malignant potential in a variety of cancers.
Women with denser breast tissue have an increased risk of developing
breast cancer [1], and desmoplastic reaction was associated with
poorer survival in a long-term breast cancer study [2]. The presence of
a fibrous stroma was also associated with poor prognosis in lung
squamous cell carcinoma [3], while stromal α-smooth muscle actin
(α-SMA) expression was correlated with invasive squamous cell
carcinoma of the cervix [4]. CAFs are significant contributors to
desmoplasia and the composition of the tumor stroma, producing
scaffolding for tumor growth through deposition of extracellular
matrix (ECM) and supplying the microenvironment with a dense
reservoir of tumor-promoting factors [5–7]. Tumor cell–CAF
crosstalk has been shown to have profound effects on tumor
angiogenesis [8], a critical step in tumor progression [9], both
directly, through production of cytokines and chemokines, and
indirectly, through production of matrix degrading molecules that act
to remodel the ECM and release stored growth factors. Further,
studies have demonstrated that this crosstalk is necessary for CAF
phenotype and function [10,11]. Clinically, increased solid tumor
vascular density has been associated with increased tumor grade [12],
poor prognosis [13], increased metastatic potential [14,15], and
shorter patient survival [16].
CAFs are heterogeneous [17–19] with respect to their phenotype,
genetic diversity [18,20], and complex secretory profiles [21–23].
This has been demonstrated by altered gene expression profiles of
CAFs in colon cancer [24], oral squamous cell carcinoma [25], non–
small cell lung carcinoma [26], and breast cancer [27–29]. In prostate
cancer models, heterogeneity in transforming growth factor–β
(TGF-β) receptor II expression in CAFs was associated with increased
tumorigenicity [30]. Because of the heterogeneity of the CAF
population, CAFs cannot be defined by a single marker but are
generally defined as a cell that expresses ECM molecules, matrix
metalloproteinases (MMPs), and one or more markers such as
vimentin,α-SMA, fibroblast activation protein (FAP), and/or fibroblast
specific protein [31]. CAF heterogeneity is believed to be due, in part, to
their proposed multiple origins (reviewed in [5,32–34]). Traditionally,
it was thought that CAFs arose from resident fibroblasts [35,36];
however, additional sources have recently been suggested including
cancer-associated adipocytes [37,38], endothelial cells [39,40],
epithelial-to-mesenchymal transition (EMT) [41], and bone marrow
cells [42]. Given that the CAF population is a significant driver of the
pro-tumorigenic microenvironment in many solid tumors, therapeutic
targeting of the CAF population may lead to better control of tumor
progression. However, the multiple origins and thus heterogeneity of
the CAF population suggest the challenge of identifying an appropriate
anti-CAF therapeutic target and highlights the importance of
understanding the biological contributions of CAFs from each origin.
Using a unique clonal cell transplantationmethod, our laboratory has
previously identified a novel hematopoietic stem cell (HSC) origin for
CAFs in multiple murine tumor models [43]. In this transplantation
method, a clonal population from a single sorted enhanced green
fluorescent protein (EGFP+) Lin−Sca-1+c-kithiCD34− HSC was
transplanted into lethally irradiated mice. In these studies [43], clonally
engrafted mice were injected subcutaneously with syngeneic Lewis lung
carcinoma (LLC) or melanoma cells. Tumors extracted from these mice
contained EGFP+ cells with a fibroblastic morphology and heteroge-
neous expression of collagen IαI (Col IαI) and α-SMA [43],hallmarks of activated fibroblasts [6,7]. Findings from these studies
show that approximately 8% of HSC-derived CAFs (HSC-CAFs)
expressed procollagen IαI [43]. In addition, in clonal transplantation
studies, the HSC-CAF precursor was identified as a circulating
fibroblast precursor population that is present in the peripheral blood,
is elevated with increased tumor burden, and matures into a CAF
phenotype (i.e., collagen and α-SMA expression) with exposure to
tumor conditioned media [44]. While these previous studies
demonstrated the contribution of HSC-derived cells to the CAF
population, their functional roles in tumor progression have not yet
been determined. In the present study, we sought to isolate and profile
HSC-CAFs and test the hypothesis that HSC-CAFs promote tumor
progression through deposition of ECM, ECM remodeling, and
paracrine production of pro-angiogenic factors. A method for isolating
HSC-CAFs from two murine solid tumor models (LLC and E0771
breast cancer) was developed in clonally engrafted animals. Profiling
studies demonstrate that fibroblastic cells isolated by this method are
derived from the HSC and have a CAF phenotype based on molecular
and immunohistochemical analyses. Functionally, we have demonstrated
that HSC-CAFs contribute to ECM and ECM remodeling. Co-injection
studies show that HSC-CAFs promote tumor growth and vascularization
in vivo. In vitro endothelial tube formation assays reveal production of
vascular endothelial growth factor A (VEGF-A) and TGF-β1 as a
mechanism by which HSC-CAFs promote vascularization and regulate
vascular patterning. The studies herein represent, to our knowledge, the
first isolation and profiling of CAFs of a specific HSC origin and reveal
that HSC-CAFs promote tumor progression by contributing to ECM
deposition, ECM remodeling, and tumor vascularization. These studies
are essential toward understanding the functional contributions of CAFs
from one source and may provide important insight into the therapeutic
targeting of fibroblasts in the tumor microenvironment.
Materials and Methods
Ethics Statement
Researchwas conducted in strict accordancewith guidelines set by the
US Public Health Service Policy on Humane Care and Use of
Laboratory Animals and the Veterans Affairs Medical Center (VAMC)
Institutional Animal Care and Use Committee (IACUC), approved by
the RalphH. Johnson VAMC IACUC (Charleston, SC) under Protocol
No. 541, VA AWA-A3137-01 (expiration 31 December 2017). All
efforts were made to minimize suffering in animal studies. Human
umbilical vein endothelial cells (HUVECs) were purchased from a
commercially available source (Life Technologies, Carlsbad, CA).
Mice
C57Bl/6/CD45.1 breeders were from Jackson Laboratories, (Bar
Harbor, Maine). EGFP breeders (C57Bl/6/CD45.2 background) were
provided by Dr M. Okabe (Osaka University, Osaka, Japan) [45]. Mice
were bred and maintained in the Animal Research Facility, VAMC.
Research was conducted in accordance with guidelines set by the US
Public Health Service Policy on Humane Care and Use of Laboratory
Animals and the VAMC IACUC.
Antibodies
Fluorochrome-conjugated, biotinylated or purified versions of the
following antibodies were used: anti–Sca-1 (anti–Ly-6A/E[D7]), anti–c-kit
(anti-CD117[2B8]), anti–Gr-1 (anti–Ly-6G[RB6-8C5]), anti-CD45R/
B220 (RA3-6B2), anti–Thy-1.2 (30-H12), anti–TER-119 (TER-119),
anti-CD3e (145-2C11), anti-CD45 (leukocyte common antigen,
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anti-CD45.1 (A20) from BD Biosciences (San Jose, CA); anti-F4/80
(BM8) and anti-CD34 (RAM34) from eBioscience (San Diego, CA);
anti–β-actin–HRP (5125 s) from Cell Signaling Technology (Danvers,
MA); anti–Col I from Rockland (Limerick, PA); anti–α-SMA
(ab5694), anti-vimentin, anti–wide spectrum cytokeratin (WS CyK),
anti–Col I (ab21286), anti-CD45 (ab10558), anti-CD31 (ab13970),
and anti-GFP (anti-green fluorescent protein, ab28364) from Abcam
(Cambridge, MA); VEGF-A, TGF-β1 neutralizing antibodies from
R&DSystems (Minneapolis,MN); isotype control antibodies fromBD
Biosciences; secondary antibodies from Jackson ImmunoResearch
(West Grove, PA) or BD Pharmingen (San Diego, CA).
Clonal Cell Transplantation
Clonal cell transplantation was performed as previously described
[43,44,46,47]. Briefly, lineage negative (Lin−) cells were isolated from
bone marrow of C57Bl/6-EGFP/CD45.2 mice by negative selection
following staining and DynaBead removal of B220, Gr-1, CD4, CD8a,
and TER-119 positive cells. Lin− cells were stained with antibodies to
Sca-1, c-kit, and CD34 and then incubated withHoechst 33342 (Sigma,
St. Louis, MO; 5 mg/ml). Single Lin−Sca-1+c-kithiCD34− side
population cells were deposited into individual wells of 96-well culture
plates (MoFlo CyClone System, Beckman Coulter, Inc., Indianapolis,
IN). Eighteen hours post-deposition, wells containing single cells were
identified and cultured for 7 days in α-modification of Eagle’s medium
(αMEM; Life Technologies), 20% FBS (Atlanta Biologicals, Norcross,
GA), 10% BSA (Life Technologies), 1 × 10−2 M 2-mercaptoethanol
(Sigma), 10 μg/ml stem cell factor, and 10 μg/ml interleukin-11 (R&D
Systems). Wells containing ≤20 clonal cells were selected for
transplantation. Recipient C57Bl/6/CD45.1mice were lethally irradiated
(total body irradiation, 950 cGy). Clonal cells were injected intravenously
along with 500 CD45.1/EGFP−/Lin−c-kit+Sca-1+CD34+ radioprotec-
tive cells. These short-term repopulating cells allow the mouse to survive
the post-irradiation pancytopenia period [43,44,46–50]. The two
clonally engrafted mice herein showed total hematopoietic engraftment
of 57.6% and 83.4% EGFP+ cells from a single sorted HSC, and
multilineage engraftment of EGFP+ cells in the B cell, T cell, and
granulocyte/macrophage lineages was confirmed.
Tumor Models
Murine LLC-1 (American Type Culture Collection, Manassas, VA)
cells were propagated using standard culture methods. LLC cells were
grown to 95% confluency in RPMI 1640 containing L-glutamine (Life
Technologies) with 10% FBS and penicillin/streptomycin (5% CO2,
37°C). LLC cells were resuspended [5 × 105 cells per 100 μl of
phosphate-buffered saline (PBS)] and injected subcutaneously into
anesthetized 14- to 16-week-oldmice.Murine breast cancer E0771 cells
were a kind gift to Dr Dennis Watson from Dr Ray B. Ratna (St Louis
University, St Louis, MO). Cells were grown to 95% confluency in
Dulbecco's modified Eagle's medium (Life Technologies) containing
20%FBS (5%CO2, 37°C). E0771 cells were resuspended (5 × 10
5 cells
per 50 μl of PBS) and injected orthotopically into the fourth mammary
fat pad of anesthetized 10- to 12-week-old female mice. LLC and
E0771 tumors were harvested at maximal size allowed by local IACUC.CAF Isolation
LLC or E0771 tumors were extracted, cleared of surrounding
tissue, minced, and placed in collagenase solution [0.5 mg/ml
collagenase (Sigma) in Dulbecco's modified Eagle's medium (LifeTechnologies)] for 35 minutes at 37°C. The suspension was vortexed,
filtered through a 70 μM cell strainer, and centrifuged. The pellet was
washed in 0.1% BSA/PBS and resuspended in 20% FBS/αMEM
supplemented with penicillin/streptomycin and cultured (5% CO2,
37°C). After 3 to 5 days, cells were trypsinized with 0.25%
trypsin-EDTA until tumor cells were released from the plate as visually
assessed by microscopy, whereas stromal cells were retained. Plates were
washed three times, and fresh culture medium was added. Cells were
serially trypsinized to continually reduce tumor cell population before
use for further studies. Primary CAFs were used below passage three.
Skin Fibroblast Isolation
Dorsal skin was harvested from euthanized EGFP+ mice, depilated,
minced, and digested in 0.25% trypsin/EDTA for 4 hours at 37°C.
Trypsin was inactivated, and cells were collected by centrifugation. The
pellet was washed, triturated, resuspended in 20% FBS/αMEM
containing penicillin/streptomycin, and cultured (5% CO2, 37°C).
Primary skin fibroblasts were used below passage three.Quantification of HSC-CAFs
Fluorescent and differential interference contrast (DIC) images of
non-passaged isolated cells were taken at ×100 magnification (10 per
sample). Numbers of EGFP+ and EGFP− cells, expressed as percent ± SD,
were quantified by two independent observers from two animals.
Immunofluorescence
Cultured cells were fixed in 4% paraformaldehyde, permeabilized
in 0.02% Triton X-100/PBS, serum blocked, and incubated with
primary antibodies. Samples were washed in PBS and serum blocked
before incubation with fluorochrome-conjugated secondary anti-
bodies. Hoechst 33342 was used as a nuclear marker. For paraffin-
embedded tumors, sections were deparaffinized in histoclear and
dehydrated in alcohols, and heat-mediated antigen retrieval was performed
in citrate buffer (Vector Laboratories, Burlingame, CA). Sections were then
permeabilized in 0.02%TritonX-100/PBS, serumblocked, and incubated
with anti-GFP antibodies followed by fluorochrome-conjugated secondary
antibodies. Hoechst 33342 was used as a nuclear marker.Quantitative Reverse Transcription–Polymerase Chain Reaction
Total RNA was extracted using the QIAshredder and RNeasyPlus
Mini Kit (Qiagen, Boston, MA). Total RNA concentration was
measured using the NanoDrop ND-1000 spectrophotometer (Nano-
Drop Technologies,Wilmington, DE). RNAwas reverse transcribed in
a 20-μl reaction using iScript (Bio-Rad, Hercules, CA). Real-time
polymerase chain reaction (PCR) was performed in a 10-μl reaction
with 2.5 μl of reverse transcribed cDNA (2.5 ng/μl), 5 μl of Bio-Rad
SsoFast Probes Supermix, 0.1 μl of both forward and reverse primers
(200 nM; Supplementary Table S1), and 0.1 μl of probe from the
Universal Probe Library System (Roche, Florence, SC) in a Roche
LightCycler 480. Cycling conditions were given as follows: preincuba-
tion, 95°C (10 seconds); 50 cycles of denaturation at 95°C (5 seconds);
annealing/extension at 60°C (30 seconds) with a single data acquisition
taken at the end of each extension; and cooling at 40°C (30 seconds).
Triplicate reactions were run for each sample. Relative gene expression
was quantified on the basis of Ct value measured against an internal
standard curve for each specific primer set using LightCycler 480–
supplied software. Sample concentration was normalized to ribosomal
protein encoding gene RPL13A. Isolated skin fibroblasts were used as a
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verify RT and PCR conditions given that these cells have an activated
phenotype in vivo during wound healing and are activated by isolation
and adherence in vitro (Supplementary Figure S1). In all experiments,
no RT served as a negative control for DNA contamination and water
served as an internal control for contamination.
Microscopy
Imaging was performed using a Nikon Eclipse Ti-U, 90i, or A1R/
confocal microscope equipped with DIC optics and long band-pass
GFP excitation cubes. Images were processed using NIS Elements
(Nikon, Tokyo, Japan), ImageJ (NIH, Bethesda, MD), and Adobe
Photoshop CS5 (Adobe Systems, San Jose, CA).
Flow Cytometry
Cells were trypsinized and recovered in culture media for aminimum
of 30 minutes at 37°C in 5% CO2. Cells were resuspended in PBS and
were blocked in 4% donkey serum (Jackson ImmunoResearch) and
mouse Fc receptor block (Miltenyi Biotec, San Diego, CA) for 20
minutes. Antibodies to cell surface proteins were added for 15 minutes
at 4°C in the dark. Cells were washed in PBS and fixed using fixation
and permeabilization buffer according to the manufacturer’s instruc-
tions (BD Biosciences). Cells were stained in Perm/Wash buffer (BD
Biosciences) with antibodies to intracellular proteins for 15 minutes at
4°C in the dark. Cells were washed in Perm/Wash buffer, and secondary
antibody was added for 15 minutes at 4°C in the dark. Cells were
washed in Perm/Wash buffer and resuspended in PBS and analyzed
using an LSR Fortessa Cytometer (BD Biosciences). Fluorescence
minus one controls were used to set gates. Data were analyzed using
FlowJo v7.6.5 and v10 (TreeStar Inc, Ashland, OR).
MMP Activity Assay
MMP activity in HSC-CAF conditioned medium (HSC-CAF-CM/
CAF-CM) or αMEM was determined using a pan-specific MMP
quenched fluorogenic peptide hydrolysis assay (OmniMMP; Enzo
Laboratories, Farmingdale, NY). Briefly, equal amounts (volume loaded)
of CAF-CM or αMEM control medium were incubated for 8 hours at
37°C with a quenched fluorogenic peptide that contains a pan-specific
MMP hydrolysis site (OmniMMP; Enzo Laboratories, Farmingdale,
NY). Upon cleavage of the peptide by activeMMPs (MMP-1, -2, -3, -7,
-8, -9, -10, -12, -13, -14, -19, and -20), the quenching group is released
and, once sufficiently separated from the fluorescent group, allows a
fluorescent signal to be detected. Fluorescence was measured and
recorded on a fluorescentmicroplate reader (SpectraMax-M3;Molecular
Devices, Sunnyvale, CA) and compared to a standard curve.
Western Blot
Isolated HSC-CAFs were washed twice with ice-cold Hank’s buffered
saline solution (HBSS, Life Technologies). Then, cells were lysed with
RIPA with 1 mM PMSF (phenylmethylsulfonyl fluoride protease
inhibitor) on ice for 15 minutes. The lysate was transferred into a
prechilled tube and centrifuged at 12,000 rpm for 15minutes at 4°C, and
the supernatant was used for assay. Protein was estimated using
bicinchoninic acid method according to the manufacturer’s protocol
(Thermo Fisher Pierce BCA kit, Thermofisher, Waltham, MA). The
lysate was then heated to 95°C for 5minutes with loading buffer (Bio-Rad
161-0737) according to the manufacturer’s protocol. Equal amounts of
the sampleswere loaded into eachwell, and electrophoresis was performedand transferred to a nitrocellulose membrane. The membranes were
blocked with 5% milk for 30 minutes and incubated overnight in the
primary antibodies. Anti–Col I antibody (1/1000 dilution), anti-SMA (1/
1000 dilution), and anti–β-actin–HRP-conjugated antibody (1:3000)
were used. This was followed by the appropriate secondary antibody for 1
hour at room temperature with rocking inmilk. The blots were visualized
using Bio-Rad Clarity Western ECL (170-5060).
Co-Injection Study
EGFP+ CAFs or EGFP− LLC cells were resuspended in sterile PBS and
subcutaneously injected into 14- to 16-week-old C57Bl/6/CD45.1 mice
as follows: 300,000 HSC-CAFs/0.1 ml, 100,000 LLCs with 300,000
HSC-CAFs/0.1 ml, or 100,000 LLCs/0.1 ml. Tumor length and width
were measured with calipers (length × width). Following euthanasia, the
tumor was excised, measured (length × width × height), and weighed.
Immunohistochemistry and Vessel Quantification
Paraffin sections (six per tumor) from LLC (n = 3) and LLC + CAF
(n = 4) cohorts were deparaffinized in xylenes, dehydrated in alcohols,
and stained with antibodies to CD31 using a rabbit IgG kit (Vector
Laboratories) and NovaRed substrate (Vector Laboratories). Sections
were taken at least four paraffin sections apart (~20 μm) to ensure the
same vessels were not counted twice. Average number of blood vessels
per field was quantified in three high power fields (200×) per section.Tube Formation Assay
HUVECs (purchased from Life Technologies) were cultured using
standard culture methods in HUVEC medium [medium 200
supplemented with low serum growth supplement (Life Technologies)]
and used below passage five. HUVECs were resuspended (18.75 × 103
cells per 200 μl) in HUVEC medium, αMEM (Life Technologies), or
HSC-CAF-CM. Neutralizing antibodies to VEGF-A (0.06 μg/ml) or
TGF-β (10 μg/ml) were added to HSC-CAF-CM for inhibition studies.
Cells were plated onto 48-well tissue culture plates coated with 50 μl of
Geltrexmatrix (Life Technologies) and incubated for 16 to 18 hours (5%
CO2, 37°C). Cells were stained [Calcein AM, Dead Red dye (LIVE/
DEADCell Imaging Kit, Life Technologies)], and individual wells were
imaged (40×). Nodes were defined as a branching point with two or
more neighboring pixels and segments as a length adjoining two nodes.
Vascular pattern was analyzed on the basis of methods adapted from
[51]. Themean length of a bisecting line through an avascular space (Ma)
and the mean diameter of the adjacent vascular area (Mv) of complete
networks were calculated (μm). A minimum of three independent
samples per group and two images per sample were quantified.Collection of CM and ELISA
HSC-CAFs were starved in serum-free αMEM overnight (16-18
hours), and HSC-CAF-CM was centrifuged and used for ELISA and
tube formation assays. TGF-β1 and VEGF-A ELISA (R&D Systems)
results were normalized to protein levels using a BCA protein
quantification kit (Thermo Fisher Pierce BCA kit). Data presented
are pg/ml per 1000 μg of protein. Samples were analyzed with a
SpectraMax-M2 microplate reader (Molecular Devices).Statistics
Analysis was conducted using GraphPad Prism 5 software (GraphPad
Software, La Jolla, CA). Data were presented as themean ± standard error
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regarded as statistically significant (indicated by * or ψ in figures).
Results
Isolation of HSC-CAFs
Our previous in vitro and in vivo studies identified the HSC as a
novel source of CAFs and their circulating fibroblast precursors
(CFPs) in solid tumor [43,44]. However, the functional roles of
HSC-CAFs have not yet been investigated. To allow for lineage
tracing of cells originating from a single HSC based on their EGFP
expression, we first reconstituted the bone marrow of lethally
irradiated mice with a clonal population of cells derived from a single
EGFP+ HSC as described previously [43,44,46,47]. Total hemato-
poietic engraftment and multilineage hematopoietic engraftment in B
cell, T cell, and granulocytes/macrophages were confirmed. Next, to
generate HSC-CAFs, syngeneic EGFP− LLC cells were subcutane-
ously injected into these clonally engrafted mice, and tumors were
allowed to progress to allow for in vivo recruitment and differentiation
of mature HSC-CAFs. To isolate HSC-CAFs, resulting tumors were
digested in collagenase and plated as a mixed population of EGFP+
and EGFP− cells, wherein EGFP expression indicates cells arising
from the clonal EGFP population transplanted from a single HSC.
EGFP− cells in culture are either tumor cells or fibroblasts from
alternative sources, e.g., resident fibroblasts before transplantation.
Cells underwent serial trypsinization to remove less adherent tumor
cells, resulting in retention of a population of cells highly enriched for
EGFP+ HSC-derived cells with a fibroblastic morphology. DIC
images of cells were overlaid with fluorescent images to quantify
EGFP+ (HSC-derived) and EGFP− cells (Figure 1A). Quantitative
analysis as described in the Materials and Methods section revealed
that EGFP+ HSC-derived fibroblast-like cells represented 79.41 ± 5.76%
of the population isolated by this method.
Molecular and Immunohistochemical Profiling of HSC-CAFs
Given that CAFs are a heterogeneous population and that there is no
single marker for CAFs, a combination of several markers is used to
identify CAFs [18,52]. Therefore, HSC-derived EGFP+ fibroblast-like
cells from clonally engrafted mice were profiled by qRT-PCR and
immunohistochemical analyses using a panel of standard fibroblast
markers to confirm HSC origin and CAF identity. Molecular analysis
by qRT-PCR of these cells showed mRNA expression of CD45, a
pan-hematopoietic marker, indicating HSC origin (Figure 1B). LLC
cells were negative for CD45 mRNA expression. Immunostaining
confirmed that EGFP+ cells also expressed CD45 [53] (Figure 1C).
Classic fibroblast/activated fibroblast markers including Col I, α-SMA,
FAP, and vimentin were then profiled by mRNA analysis (Figure 2A).
LLC cells did not express Col I or α-SMA, as assessed by mRNA
analysis. LLC cells did express vimentin, a marker associated with an
epithelial cell that has undergone EMT [54], and FAP but at
significantly lower levels than that observed in the CAFs (P ≤ .001
and P = .0121, respectively). Production of MMPs has been associated
with both the CAF phenotype and their function in critical components
of tumor progression, including matrix remodeling and release of stored
growth factors and vascularization [55–57]. Therefore, as an additional
analysis of the activated fibroblastic nature of this population, mRNA
expression of MMP-2, -3, -9, and -14 was demonstrated by qRT-PCR
(Figure 2B). As further confirmation of the fibroblastic nature of the
isolatedHSC-derived population, immunostaining revealed expression ofCol I, α-SMA, and vimentin protein (Figure 2C). Negative immuno-
staining with antibodies to F4/80, a macrophage marker [58], and WS
CyK, an epithelial marker, demonstrated that EGFP+/HSC-derived cells
were not macrophages or epithelial cells (Figure 2C). No primary
antibody controls are shown in Supplementary Figure S2. Together, the
fibroblastic morphology and gene and protein expression of a panel of
fibroblastic markers confirm the CAF identity of EGFP+/HSC-derived
cells obtained through our isolation method.
The lethal irradiation necessary to condition recipient mice for bone
marrow transplantation with a clonal population of cells derived from a
single sorted HSCmay affect the behavior and function of HSC-CAFs.
Therefore, to avoid any effects of irradiation, we applied the same
HSC-CAF isolation method to non–bone marrow transplanted mice
and confirmed HSC origin by CD45 expression and CAF identity by
fibroblast-associated marker expression. EGFP/CD45.2 mice were
injected subcutaneously with EGFP− LLC cells, and tumors were
processed and cells subjected to serial trypsinization as described above.
EGFP/CD45.2mice were used to allow for distinction between EGFP+
stromal cells from EGFP− tumor cells. Isolated EGFP+ cells had a
fibroblastic morphology and expressedCD45mRNA at similar levels to
those seen in CAFs isolated from clonally engrafted mice, indicating
their HSC origin (compare Figures 3A and 1B). Expression of CD45
protein was confirmed by immunofluorescence staining (Figure 3B).
qRT-PCR analysis of the same isolated cells demonstrated expression of
mRNA for Col I, α-SMA, FAP, vimentin, andMMPs (Figure 3, C and
D). Together with CD45 expression, this confirms isolation of a
population of cells highly enriched for HSC-CAFs. As shown in
representative images, expression of Col I, α-SMA, and vimentin
protein by EGFP+ HSC-CAFs was confirmed by immunofluorescence
staining (Figure 3E). No primary antibody controls are shown in
Supplementary Figure S2. Together, findings using both clonally
engrafted mice and non–bone marrow transplanted mice demonstrate
an HSC origin for CAFs, profile the HSC-CAF phenotype, and
confirm we have established an effective method of cell isolation to
study the functional contributions of HSC-CAFs to tumor progression.
HSC-CAFs Contribute to a Pro-Tumorigenic Microenvironment
To quantitatively assess the contribution of HSC-derived cells to
the α-SMA and Col I positive populations of isolated cells, flow
cytometric analysis was used to determine the percentage of EGFP+
cells isolated from tumors of non–bone marrow transplanted mice
that co-expressed CD45 with Col I or α-SMA (Figure 4A).
Quantitative analysis from multiple mice demonstrated that 68%
(±0.5%) of EGFP+ cells co-expressed CD45 and Col I and 90%
(±0.1%) of EGFP+ cells co-expressed CD45 and α-SMA. ECM
composition and stiffness are correlated with poor patient prognosis
[1,59,60]. Two factors shown to play important roles in this are Col I
([61] and reviewed in [62]) and α-SMA [4,32]. To determine
whether HSC-CAFs actively contribute to production of collagen and
expression of α-SMA in the tumor microenvironment, Western blot
analysis for Col I and α-SMA was also performed (Figure 4B). In
addition to matrix deposition, CAFs have been shown to play a role in
matrix remodeling through production of MMPs. Therefore, to
determine whether CAFs originating from the HSC contribute to
these processes, we examined HSC-CAFs for the production of active
MMPs. CAF-CM was added to a fluorogenic OmniMMP substrate
that emits fluorescence when cleaved by MMPs, and the resulting
fluorescence is measured over time. CAF-CM resulted in increased
fluorescence of the substrate over time, indicating that HSC-CAFs
Figure 1. Isolation of HSC-CAFs from clonally engrafted mice. (A) Representative image of EGFP+ (HSC-derived) and EGFP− cells
(asterisks) isolated from an LLC tumor grown in a clonally engrafted mouse. (B) qRT-PCR analysis of CD45 expression in HSC-CAFs
(black bar) and LLC tumor cells (hatched bar; *P≤ .0001). (C) DIC and immunofluorescence staining of representative isolated cells show
morphology (DIC), nuclei (Hoechst dye, HO), expression of EGFP, and CD45 (Ab stain). Merged images (right panels) represent EGFP,
HO, and antibody stain (Ab stain). Secondary only (no primary antibody) controls for immunofluorescence images are depicted in
Supplementary Figure S2. Bars, 100 μm (B) and 25 μm (D).
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MMPs and production of Col I and α-SMA indicate that HSC-CAFs
are important contributors to the pro-tumorigenic microenvironment.
HSC-CAFs Enhance Tumor Growth In Vivo
To test the in vivo functional ability of HSC-CAFs to affect tumor
progression, EGFP+ HSC-CAFs were isolated from LLC tumors from
non-transplanted EGFP/CD45.2 mice. These EGFP+ HSC-CAFs were
then co-injectedwith LLCcells (LLC+CAF) intoC57Bl/6mice in a ratio
of 1:3 (LLCs:CAFs). Control cohorts of mice were injected with either
LLC cells alone (LLC) or HSC-CAFs alone (CAF). The LLC cohort
served as a control for tumor growth rate. Tumor size was measured in
each cohort longitudinally (Figure 5A). Tumors were not observed in the
CAF cohort, demonstrating that HSC-CAFs were not tumorigenic and
confirming effective isolation of CAFs with minimal tumor cell
contamination. Tumors from the LLC + CAF cohort grew faster than
tumors in the LLC cohort (growth curve slope 0.19 ± 0.02 vs 0.07 ± 0.01,
P ≤ .0001). In addition, tumors from co-injection cohort animals had a
significantly larger size at each time point from day 14 to harvest (P =
.0445, day 14;P = .009, day 16;P = .0046, day 18;P = .0075, day 20). At
endpoint, tumors from the LLC +CAF cohort were about two-fold larger
by weight than tumors in the LLC cohort (0.98 ± 0.33 g vs 0.45 ± 0.07 g,
respectively, P = .0433; Figure 5,B andC). The pattern of EGFP+ cells in
the LLC + CAF cohort tumors is shown by EGFP+ staining in tumor
sections (Figure 5D), demonstrating that the co-injected HSC-CAF
population persists as the tumors grow. The increased growth rate, size,
andmass of tumors from co-injectedmice indicate that HSC-CAFs play a
significant role in promoting tumor growth in vivo.
HSC-CAFs Promote Tumor Vascularization In Vivo
Angiogenesis is critical toward tumor growth, and because the
tumors from the co-injected mice (LLC + CAF cohort) appeared to be
more vascularized on excision than those from LLC cohort mice(Figure 5C), we sought to determine whether the observed increased
growth was because of the ability of HSC-CAFs to promote blood
vessel formation in vivo. Paraffin sections of tumor from LLC + CAF
and LLC cohorts harvested at endpoint were stained using antibodies
to CD31, an endothelial cell marker. Quantitative analysis showed
that tumors from co-injected mice were highly vascularized
(Figure 5E), with an about three-fold increase (P ≤ .0001) in the
average number of blood vessels per field (12.0 ± 0.7 vessels per field)
over that of LLC-only cohort tumors (4.4 ± 0.3 vessels per field;
Figure 5F). These findings suggest that HSC-CAFs enhanced tumor
growth, in part, by promoting tumor vascularization as reflected by
increased blood vessel density in vivo.HSC-CAFs Promote Angiogenesis In Vitro
To determine the mechanism by which HSC-CAFs promote
tumor vascularization and to establish whether HSC-CAFs promote
blood vessel formation through paracrine factors, HUVECs were
plated onto a Geltrex matrix in serum-free αMEM conditioned
medium from HSC-CAFs (HSC-CAF-CM) isolated from LLC
tumors. Serum-free αMEM served as a negative control, and
complete HUVEC medium was used as a positive control. HUVECs
were stained with Calcein AM dye to allow for better visualization of
networks by fluorescence microscopy. Tube formation assay showed
that HSC-CAF-CMpromoted tube formation over that ofαMEMand
to a similar extent as HUVEC medium positive control (Figure 6A).
Images of the tube formation assay were quantitatively evaluated
for numbers of nodes, numbers of endothelial segments, and overall
vascular pattern (Figure 6B). Analysis revealed a statistically
significant increase (P b .0001) in the number of nodes resulting
from treatment with CAF-CM (26.9 ± 2.3) over control αMEM
(3.5 ± 1.7) and a significant increase in the number of endothelial
segments (P b .0001) with CAF-CM (27.1 ± 3.3) over αMEM (2.3 ±
Figure 2. Characterization of HSC-CAFs from clonally engraftedmice. (A) qRT-PCR analysis of activated fibroblast markers Col I (*P≤ .0001),
α-SMA (*P= .0031), FAP (*P= .0121), and vimentin (*P≤ .0001) in HSC-CAFs (black bars) and LLC tumor cells (hatched bars). (B) qRT-PCR
analysis ofMMP-2 (*P= .0035),MMP-3 (*P≤ .0001),MMP-9 (*P≤ .0001), andMMP-14 (*P= .0002) in HSC-CAFs (black bars) from clonally
engrafted mice and LLC tumor cells (hatched bars). (C) DIC and immunofluorescence staining of representative isolated cells show
morphology (DIC), nuclei (Hoechst dye, HO), and expression of EGFP, Col I, α-SMA, vimentin, F4/80, and WS CyK. Bars, 25 μm (C).
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between CAF-CM and HUVEC medium treatment (P = .5958 and
P = .7469, respectively). Vascular pattern can be reflected in the ratio
of vascular to avascular space, as calculated by measurements of Ma
and Mv diameters [51]. For example, a fine reticular vascular
network has a large Ma to small Mv, while a larger, more sinusoidal
network has a small Ma to large Mv ratio [51]. On the basis of this
algorithm [51], HUVEC medium cultures revealed a fine vascular
network indicated by increased Ma to Mv ratio (Figure 6B, Ma:Mv).
HUVECs cultured in HSC-CAF-CM resulted in a network pattern
similar to HUVEC control medium with Mv (35.2 ± 4.8 vs 53.1 ±
8.3, respectively, P = .0507) and Ma (362.0 ± 16.9 vs 331.3 ± 20.7,
P = .2497). Negative control (αMEM) did not support vascular
patterning, and there was no significant difference in cell death
between HUVECs cultured in αMEM and HSC-CAF-CM (data
not shown, P = .1690). These data indicate that HSC-CAFs promote
endothelial tube formation through production of paracrine factors.HSC-CAF Promotion of Vascular Patterning Is VEGF-A and
TGF-β1 Dependent
VEGF and TGF-β are known to play a role in angiogenesis and
vascular patterning; thus, we sought to determine whether HSC-CAF
promotion of endothelial tube formation is supported through these
factors. ELISA analysis of HSC-CAF-CM as used in tube formation
assays demonstrated that HSC-CAFs produce both VEGF-A
(289.60 ± 37.38 pg/ml) and TGF-β1 (89.50 ± 2.47 pg/ml), factors
commonly associated with CAF populations (Figure 7A). This
expression was confirmed by qRT-PCR (Figure 7B). As a positive
control, production of VEGF-A and TGF-β1 by cultured primary
skin fibroblasts was measured by ELISA (VEGF-A, 263.30 ± 5.03 pg/ml;
TGF-β1, 30.64 ± 4.46 pg/ml) and qRT-PCR to allow for comparison of
CAF-produced factors to an activated cell type known to produce
biologically relevant levels of angiogenic factors, including VEGF and
TGF-β [63,64]. To assess whether production of these factors by
HSC-CAFs contributed to HUVEC tube formation, neutralizing
Figure 3. Expression profiles of HSC-CAFs. (A) qRT-PCR analysis of CD45 in HSC-CAFs isolated from non-transplanted mice injected with
LLC tumor cells (black bar) and LLC tumor cells (hatched bar; *P ≤ .0001). (B) DIC and representative immunofluorescence staining of
EGFP, nuclear (Hoescht dye, HO), and CD45 (Ab stain) expression in HSC-CAFs are depicted. (C) qRT-PCR analysis of activated fibroblast
markers Col I (*P= .0001), α-SMA (*P≤ .0001), FAP (*P= .0176), and vimentin (*P≤ .0001) in HSC-CAFs (black bars) and LLC tumor cells
(hatched bars). (D) qRT-PCR analysis of MMP-2 (*P = .5931), MMP-3 (*P ≤ .0001), MMP-9 (*P = .0012), and MMP-14 (*P = .0007) in
HSC-CAFs (black bars) and LLC tumor cells (hatched bars). (E) DIC and representative immunofluorescence staining of nuclei (Hoescht
dye, HO), EGFP, and Col I, α-SMA, and vimentin (Ab stain) expression in HSC-CAFs are depicted. Bars, 25 μm (B, E).
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HUVEC tube formation assays. Morphologic comparison of HUVECs
cultured in HSC-CAF-CM versus HSC-CAF-CM with VEGF-A
neutralizing antibody revealed decreased network formation, fewer
complete vascular networks or “meshes”, and presence of cell aggregates
(Figure 7C). Quantitative comparison of networks cultured in
HSC-CAF-CM versus those cultured in HSC-CAF-CM with VEGF-A
neutralization (Figure 7D) showed a significant decrease in the number of
nodes (26.9 ± 2.3 vs 15.1 ± 3.2, respectively, P = .0107) and segments
(27.1 ± 3.3 vs 11.8 ± 3.9, respectively, P = .0094). Analysis of vascular
pattern indicated similar Ma in HSC-CAF-CM with VEGF-A
neutralization (327.5 ± 32.5) versus CAF-CM (362.0 ± 16.9, P =
.3150). An approximate 31% reduction in Mv was seen with VEGF-A
neutralization; however, this difference was not found to be statisticallysignificant (24.2 ± 2.8 in HSC-CAF-CM with inhibitor vs 35.2 ± 4.8 in
HSC-CAF-CM; P = .1758). Together, morphologic and quantitative
analyses suggest that neutralization of VEGF in HSC-CAF-CM skews
the vascular patterning toward a finer vascular network with larger
avascular spaces, increased cell aggregates, and decreased nodes and
segments, overall resulting in inhibited tube formation.
On the basis of morphology, vascular pattern was also affected by
the addition of TGF-β neutralizing antibody to HSC-CAF-CM.
Vascular networks appeared complete, with similar mesh pattern to
those observed with CAF-CM; however, the diameter of the tubes
formed with TGF-β inhibition appeared to be larger (Figure 7C).
While the numbers of nodes and segments did not reflect significant
differences (comparison of CAF-CM to CAF-CM with inhibitor:
nodes, 26.9 ± 2.3 vs 19.4 ± 3.1, P = .0749; segments, 27.1 ± 3.3 vs
Figure 4. HSC-CAFs contribute to the pro-tumorigenic microenvironment. (A) Representative flow cytometric analysis shows percent of
EGFP-expressing cells that co-express CD45 and Col I (68%, left panel) and those that co-express CD45 and α-SMA (90%, right panel).
Gates were set on the basis of fluorescence minus one (FMO) controls. (B) Western blot analysis shows 150 and 42 kDa bands for Col I
and α-SMA, respectively, from HSC-CAFs isolated from three biological replicates (M1, M2, and M3); β-actin loading control is shown
below. (C) Functional MMP activity assay in HSC-CAF-CM (black squares) and αMEM (empty circles) shows that HSC-CAF-CM contains
active MMPs (*P ≤ .05).
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of nodes (27.90%) and segments (31.33%) with TGF-β inhibition
(Figure 7D). Analysis of vascular pattern reflected significant
morphologic changes on inhibition of TGF-β. While Ma remained the
same compared to HUVEC cultures treated with CAF-CM (P = .6279),
Mv was significantly increased with TGF-β neutralization (131.8 ± 27.1
vs 35.2 ± 4.8 inCAF-CMalone,P ≤ .0001), suggesting that neutralization
of TGF-β altered vascular patterning, resulting in increased diameter of
endothelial tubes. Together, these studies demonstrate that HSC-CAFs
promote tumor vascularization and vascular patterning through paracrine
production of VEGF-A and TGF-β1.
HSC-CAFs from a Murine Model of Breast Cancer Promote
In Vitro Angiogenesis
To determine whether HSC-CAFs and their tumor-promoting
functions were tumor type specific, we profiled HSC-CAFs and examined
their impact on angiogenesis in a syngeneic E0771 breast cancer model.
E0771 tumor cells were injected orthotopically into non–bone marrow
transplanted EGFP/CD45.2 female mice, and CAFs were isolated as
described above. EGFP+ cells isolated fromE0771 tumors expressedCD45
mRNA and protein (Figure 8, A and B, respectively), supporting their
HSC origin, as well as markers of activated fibroblasts including Col I,
α-SMA, FAP, vimentin, and MMPs (Figure 8, C–E). As with LLC cells,
E0771 cells did not express CD45 or profiled fibroblast markers, with the
exception of the EMT marker, vimentin. For all immunofluorescence
staining, no primary staining controls are shown in Supplementary FigureS2. Together, gene and protein expression of CD45, as well as markers of
activated fibroblasts, indicate an HSC origin for the isolated population of
CAFs from an E0771 murine breast cancer model.
Finally, functional analysis of HSC-CAF-CM in HUVEC tube
formation assays showed that CAFs from E0771 tumors also
supported endothelial cell network formation (Figure 8, F and G).
HSC-CAF-CM from E0771 tumors compared to αMEM showed an
increase in the number of nodes (17.0 ± 3.1 vs 3.5 ± 1.7, respectively,
P = .0016) and segments (13.7 ± 3.6 vs 2.3 ± 1.2, respectively, P =
.0053). While there was no significant difference between
HSC-CAF-CM and HUVEC medium treatment with respect to
nodes (P = .1142), there was a decrease in number of segments (P =
.0280). In addition, HSC-CAF-CM from E0771 tumors promoted
network patterning where HSC-CAF-CM Ma (277.3 ± 36.7) and
Mv (67.6 ± 13.4) were similar to HUVEC medium Ma (331.3 ±
20.7, P = .1762) and Mv (53.1 ± 8.3, P = .3398). As with the LLC
model, these data demonstrate an HSC origin for CAFs in a murine
model of breast cancer and together demonstrate a role for HSC-CAFs
in ECM production, ECM remodeling, and tumor vascularization in
multiple tumor models.Discussion
Multiple origins for CAFs have been suggested (reviewed in [5,32–34]),
and understanding the roles of CAFs in various aspects of tumor
development, progression, and metastasis is expanding. Many of the
Figure 5. Effect of HSC-CAFs on tumor growth and vascularization. Measurement of size (A) and mass (B) of tumors showed that LLC +
CAF co-injection (empty triangles) resulted in larger tumors versus LLC (empty circles) injected cohort (*P b .05). No tumor was observed
in the CAF (black squares) cohort. (C) Extracted tumors from LLC and LLC + CAF cohorts; LLC + CAF cohort tumors show increased size
and gross vascularity. (D) Immunofluorescence staining for anti-GFP (red) shows that the EGFP+ HSC-CAF population persists in the
LLC + CAF cohort of tumors at endpoint (upper panels). No primary antibody staining is shown in the lower panels. Hoechst nuclear stain
is represented in blue in merged images. (E) Immunohistochemical staining for CD31 with hematoxylin counterstain demonstrates
increased vascularization (blood vessels indicated by asterisks) in the LLC + CAF cohort. (F) Quantification of blood vessels in LLC
(white bar) and LLC + CAF (black bar) from immunohistochemical staining images (*P b .05). Bar, 25 μm (D).
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the CAFs studied as they rely on laser capture microscopy for CAF
isolation, negative selection excluding CD45-expressing cells, cell lines,and in vitro activation or induction of the CAF phenotype.
Thus, the functional impact of CAFs from each specific origin on
tumor progression remains unclear. This may be important for the
Figure 6. HSC-CAF-CM supports HUVEC tube formation. (A) HUVEC tube formation assay of cells treated with αMEM (negative control),
HUVEC medium (positive control), or HSC-CAF-CM. Tubes and vascular pattern were visualized with DIC microscopy (left panels) and
Calcein AM dye (right panels). (B) Number of nodes, segments and Ma:Mv were quantified. In B, *P b .05 compared to αMEM; ns, not
significant. Bar, 250 μm (A).
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whether CAFs of differing origins have distinct roles, potentially
requiring different therapeutic targeting strategies (as reviewed in [65]
and [52]). In the current study, we have taken steps toward addressing
these questions with respect to the function of HSC-CAFs.
The method of CAF isolation developed in the current study is
advantageous in that CAFs are recruited to the primary tumor in vivo
and selected for in vitro to achieve a highly enriched primary CAF
population that can be traced back to an HSC origin. Through the
use of clonal engraftment and confirmation through expression of the
pan-hematopoietic marker CD45, we were able to isolate a
population of CAFs that are highly enriched for cells of a specific
HSC origin to conduct in vitro and in vivo analyses of their function.
Given that there is no single marker to identify a CAF, theiridentification relies on morphology and expression of multiple
markers associated with fibroblasts/activated fibroblasts [31,32].
Thus, in this study, isolated cells from two murine tumor models
were profiled for mRNA and protein expression of CD45 and a panel
of activated fibroblast markers. Expression of the combination
of markers used herein suggested this isolation method enriched
for the CAF phenotype. As further confirmation, HSC-CAFs were
also shown to be negative for expression of macrophage and epithelial
markers, suggesting they were not the result of cell fusion, macrophage
engulfment, or EMT.
Data indicate that HSC-CAFs express Col I, α-SMA, FAP, and
MMPs, factors known to affect the ECM environment, stiffness, and
composition. The expression of these factors by HSC-CAFs provides
further insight into their potential functions in vivo, suggesting that
Figure 7. VEGF-A and TGF-β from HSC-CAFs promote HUVEC tube formation. (A) ELISA of VEGF-A (left panel) and TGF-β1 (right panel) in
HSC-CAF-CM (black bars) and skin fibroblast–CM (white bars; positive control; *P b .05). (B) qRT-PCR analysis of VEGF-A (left panel) and
TGF-β1 (right panel) mRNA expression in HSC-CAFs (black bars) and skin fibroblasts (white bars; positive control). (C) DIC (left panels) and
Calcein AM dye (right panels) representative images of HUVEC tube formation assay with the addition of VEGF-A or TGF-β neutralizing
antibodies in HSC-CAF-CM. (D) Quantification of nodes (left panel) and segments (right panel) with neutralization of VEGF-A (hatched bars)
or TGF-β (white bars) in HSC-CAF-CM (black bars; *P b .05). The ratios of Ma area, Mv area, and Ma:Mv are quantified. In D, *P b .05
compared to HSC-CAF-CM. Bar, 250 μm (C).
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during the development of tumor-associated matrix. Expression of
Col I and α-SMA were demonstrated by Western blot, and flow
cytometric analysis of HSC-CAFs demonstrated that ~68% of
isolated HSC-CAFs co-express CD45 with Col I and ~90%
co-express CD45 and α-SMA. This confirms that the isolated
population is highly enriched for HSC-CAFs and that these cells are
significant contributors to matrix composition in the tumor
microenvironment. In addition to matrix deposition, matrix
remodeling is an important aspect of a pro-tumorigenic microenvi-
ronment, acting to promote growth factor release, tumor vascular-
ization, and migratory and invasive capacities of tumor cells, all of
which can promote tumor cell metastasis. Factors known to play a
role in this process include MMPs [5,31] and FAP, a membrane-
bound serine protease that is thought to be selectively expressed by
CAFs from tumors of epithelial origin [66]. In the present study, data
show mRNA expression of FAP and production of active MMPs by
HSC-CAFs. Together, these findings demonstrate contributions by
HSC-CAFs to matrix deposition, composition, and remodeling in the
tumor stroma.
Judah Folkman established that tumors could not achieve growth
beyond 1 to 2 mm without the formation of a new blood supply [9],
thus demonstrating the critical importance of vascularization togrowth and progression of solid tumor. Angiogenesis provides both a
nutrient-rich blood flow to the developing tumor and a route for
metastatic dissemination of tumor cells. Herein, we identify EGFP+
cells in the LLC + CAF cohort tumors demonstrating that the
co-injected HSC-CAF population persists as the tumors grow. A role
for HSC-CAFs in tumor vascularization was evidenced by increased
tumor size, enhanced vascularization on gross inspection, and
augmented CD31 staining of tumors from mice co-injected with
tumor cells and HSC-CAFs. Mechanistic in vitro studies showed
HSC-CAF–derived VEGF-A and TGF-β directly regulate vascular
patterning in vitro, suggesting that HSC-CAFs promote vasculariza-
tion in vivo by similar mechanisms. Increased levels of VEGF-A and
TGF-β have been clinically correlated with poor prognosis and disease
progression in several cancer models [67–70]. The studies herein
demonstrated that HSC-CAFs exhibit expression, release, and
activation of MMPs, suggesting that HSC-CAFs may also contribute
to tumor vascularization by degrading ECM to allow endothelial cell
movement, endothelial cell organization, and release of stored
pro-angiogenic growth factors. Given that both aberrant vasculariza-
tion and MMP production have been associated with increased
invasiveness of tumor cells and dissemination of aggressive tumor
initiating cells, these data suggest the potential for HSC-CAFs to
impact early pro-metastatic processes.
Figure 8. HSC-CAFs contribute to murine breast cancer. (A) qRT-PCR analysis of CD45 expression in HSC-CAFs from E0771 tumors (black
bar) and E0771 tumor cells (hatched bar; *P≤ .0001). (B) DIC and immunofluorescence staining of representative E0771 HSC-CAFs show
morphology (DIC), nuclei (Hoechst dye, HO), expression of EGFP, and CD45 (Ab stain). (C, D) qRT-PCR analysis (C) for fibroblast markers
Col I (*P ≤ .0001), α-SMA (*P = .0104), FAP (*P = .0016), and vimentin (P = .0082) and (D) MMP-2 (*P ≤ .0001), MMP-3 (*P = .0013),
MMP-9 (*P ≤ .0001), and MMP-14 (*P ≤ .0001) in E0771 HSC-CAFs (black bars) and E0771 tumor cells (hatched bars). (E) DIC and
immunofluorescence staining of representative E0771 HSC-CAFs show morphology (DIC), nuclei (HO), EGFP expression, antibody (Col I,
α-SMA, vimentin, F4/80, WS CyK) stain (Ab stain), and merged images from representative cells. (F) HUVEC tube formation assay of cells
treated with αMEM (negative control), HUVEC medium (positive control), or E0771 HSC-CAF-CM. Tubes and vascular pattern were
visualized with DIC microscopy (left panels) and Calcein AM dye (right panels). (G) Number of nodes (left panel), segments (middle panel),
and Ma:Mv (right panel) from F were quantified. In G, *P b .05 compared to αMEM and ψP = .0280 compared to HUVEC medium.
Bars, 25 μm (A, C) and 250 μm (F).
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as well as the ability of HSC-CAFs to regulate vascular patterning and
to produce active MMPs, these findings demonstrate that HSC-CAFs
are a critical component of the pro-tumorigenic microenvironment.
Thus, with our studies and others, resulting in an increased
appreciation for the roles of the tumor microenvironment in tumor
progression and metastasis, current therapeutic efforts are being
aimed at targeting both tumor cells and stromal cells (reviewed in
[6,71,72]). Devising optimal anti-stromal or anti-CAF therapiesrequires identification of suitable targets as well as the development of
reliable biomarkers that indicate the type and composition of the
tumor microenvironment in a given tumor. Elucidation of the
contribution of CAFs from different sources may inform both of
these aims.
Our studies show that HSC-CAFs, a previously underappreciated
source of CAFs, play an integral role in the development of the tumor
microenvironment and biologically impact tumor growth and
vascularization in vitro and in vivo in multiple models. HSC-CAFs,
Neoplasia Vol. 17, No. 5, 2015 HSC-CAFs as Novel Contributors McDonald et al. 447once incorporated into the tumor, share phenotypic and functional
similarities with classically identified CAFs and those derived from
bone marrow mesenchymal stem cells [42,73] in that they display an
activated phenotype, produce and remodel matrix, and contribute to
tumor growth and angiogenesis. However, the HSC-CAF is unique
in that this population may be continually recruited from the bone
marrow into circulation as a circulating fibroblast precursor [44], then
to the developing tumor mass. This recruitment potentially provides a
unique opportunity to target HSC-CAFs before their incorporation
into the tumor stroma, in addition to targeting their effects on the
pro-tumorigenic microenvironment once established in the tumor
stroma. Further, the ability to identify and trace the HSC-CAF before
its incorporation into the tumor stroma may serve as a powerful
biomarker for assessing efficacy of anti-tumor therapies.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2015.04.004.
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